Zydus Cadila gets tentative nod from USFDA for diabetes drug

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.59 per cent lower at Rs 418.30 per scrip on BSE.

Published: 11th September 2018 01:46 PM  |   Last Updated: 11th September 2018 01:46 PM   |  A+A-

diabetes drug

Image used for representational purpose only.

By PTI

NEW DELHI: Zydus Cadila has received tentative approval from the US health regulator to market Sitagliptin tablets, indicated for treating diabetes, in the American market.

The company has received tentative approval from the United States Food and Drug Administration (USFDA) for Sitagliptin tablets in strengths of 25 mg, 50 mg, and 100 mg, Zydus Cadila said in a BSE filing.

It said the drug will be produced at the group's formulations facility at SEZ, Ahmedabad.

The group has more than 217 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs).

Shares of Cadila Healthcare, the listed entity of the group, were trading 0.59 per cent lower at Rs 418.30 per scrip on BSE.

 

Stay up to date on all the latest Business news with The New Indian Express App. Download now
(Get the news that matters from New Indian Express on WhatsApp. Click this link and hit 'Click to Subscribe'. Follow the instructions after that.)

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

facebook twitter whatsapp